- Home
- ACHV vs PLRX Comparison
ACHV vs PLRX Comparison
Compare ACHV & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- PLRX
- Stock Information
- Founded
- ACHV N/A
- PLRX 2015
- Country
- ACHV Canada
- PLRX United States
- Employees
- ACHV N/A
- PLRX N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ACHV Health Care
- PLRX Health Care
- Exchange
- ACHV Nasdaq
- PLRX Nasdaq
- Market Cap
- ACHV 72.5M
- PLRX 87.0M
- IPO Year
- ACHV N/A
- PLRX 2020
- Fundamental
- Price
- ACHV $1.99
- PLRX $1.46
- Analyst Decision
- ACHV Strong Buy
- PLRX Hold
- Analyst Count
- ACHV 3
- PLRX 10
- Target Price
- ACHV $14.33
- PLRX $9.79
- AVG Volume (30 Days)
- ACHV 193.4K
- PLRX 1.4M
- Earning Date
- ACHV 05-08-2025
- PLRX 05-05-2025
- Dividend Yield
- ACHV N/A
- PLRX N/A
- EPS Growth
- ACHV N/A
- PLRX N/A
- EPS
- ACHV N/A
- PLRX N/A
- Revenue
- ACHV N/A
- PLRX N/A
- Revenue This Year
- ACHV N/A
- PLRX N/A
- Revenue Next Year
- ACHV N/A
- PLRX N/A
- P/E Ratio
- ACHV N/A
- PLRX N/A
- Revenue Growth
- ACHV N/A
- PLRX N/A
- 52 Week Low
- ACHV $1.84
- PLRX $1.10
- 52 Week High
- ACHV $5.59
- PLRX $16.52
- Technical
- Relative Strength Index (RSI)
- ACHV 31.53
- PLRX 37.18
- Support Level
- ACHV $1.98
- PLRX $1.10
- Resistance Level
- ACHV $2.28
- PLRX $1.34
- Average True Range (ATR)
- ACHV 0.24
- PLRX 0.12
- MACD
- ACHV -0.02
- PLRX 0.15
- Stochastic Oscillator
- ACHV 15.62
- PLRX 88.45
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.